Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia
-
- STATUS
- Recruiting
-
- End date
- Dec 31, 2023
-
- participants needed
- 55
-
- sponsor
- Peking University People's Hospital
Summary
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure. We reported previously that patients with relapse or refractory AL were at very high risk of relapse post allo-HSCT, with cumulative relapse rate of 50-80%. Decitabine has been demonstrated efficacy in the treatment of patients with recurrent or refractory leukemia and myelodysplastic syndrome. It was reported that the combination of decitabine, with busulfan and cyclophosphamide as a preparative regimen for allo-HSCT using HLA-matching donors was safe and effective. In this prospective, single-arm clinical trial, we aimed to examine the efficacy of combining decitabine with modified busulfan and cyclophosphamide (mBU/CY) as a preparative regimen for allo-HSCT in recurrent and refractory AL patients.
Description
Patients enrolled in this study would receive decitabine 200mgm-2d-1 on day -12 and -11 pre-HSCT. The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was modified BU/CY plus ATG (thymoglobulin; Sang Stat, France) consisting of cytarabine (Ara-C 4 gm-2d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mgkg-1d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 gm-2d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mgm-2), orally once on day -3, and ATG (2.5 mgkg-1d-1) intravenously on days -5 to -2. In matched sibling transplantations, patients received hydroxycarbamide (80 mgkg-1) orally on day -10 and a lower dose of Ara-C (2 gm-2d-1) on day -9, but otherwise an identical regimen to the HLA-mismatched patients without ATG.
BM(bone marrow) samples from patients were obtained to assess leukemia status after HSCT. The time points that we monitored BM samples included at time of allo-HSCT; 1 month, 2 months, 3 months, 4.5 months, 6 months, 9 months, and 12 months after allo-HSCT; and every 6 months thereafter to the defined endpoints or for at least until 5 years after transplantation.
Details
| Condition | Stem Cell Transplant Complications, Relapse Leukemia, Refractory Leukemia |
|---|---|
| Treatment | Decitabine, mBU/CY and ATG, mBU/CY |
| Clinical Study Identifier | NCT03799224 |
| Sponsor | Peking University People's Hospital |
| Last Modified on | 9 February 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer